One-year Serial Measurements of High-sensitivity Troponin T in Hemodialysis Patients A Randomized Placebo-controlled Sub-study Investigating Angiotensin-II-Blockade, Variation Over Time and Associations with Clinical Outcome

CURRENT STATUS: UNDER REVIEW

BMC Nephrology

Christian Daugaard Peters
Aarhus Universitetshospital

cdp@clin.au.dk Corresponding Author
ORCiD: https://orcid.org/0000-0002-4917-1535

Krista D. Kjaergaard
Department of Renal Medicine, Aarhus University Hospital

Kent L. Christensen
Department of Cardiology, Aarhus University Hospital

Bo Martin Bibby
Department of Biostatistics, Aarhus University

Bente Jespersen
Department of Renal Medicine, Aarhus University Hospital

Jens Dam Jensen
Department of Renal Medicine, Aarhus University Hospital

DOI:
10.21203/rs.2.21910/v1

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
Angiotensin II blockade, Troponin T, Hemodialysis, Randomized controlled trial, Variation, Irbesartan
Abstract

Background

Troponin T (TnT) is a well-known risk factor for negative outcome in hemodialysis (HD) patients, but little is known about variation over time, and the impact of clinical and dialysis specific factors. This study investigated the effect of angiotensin II receptor blockade (ARB), short and long-term variation in TnT and associations with clinical parameters.

Methods

In this analysis based on the SAFIR-cohort (Clinical Trials ID: NCT00791830) 81 HD patients were randomized double-blind for placebo (n=40) or angiotensin II receptor blocker (ARB) treatment (n=41) with irbesartan (150-300 mg) and followed for 12 months with six serial measurements of TnT using a high-sensitivity assay.

Results

Fifty-four patients (67%) completed follow-up. Baseline TnT-medians (min-max) were (placebo/ARB): 45(14-295)/46(10-343)ng/L. ARB-treatment did not significantly affect mean TnT-levels over the 12-month study period. Median week-to-week and one-year TnT-variation (5th-95th-percentile range) using all samples regardless of intervention were: 0(-14-10)ng/L (week-to-week) and 3(-40-71)ng/L (12 months). Median TnT-amplitude, capturing the change from the lowest to the highest TnT-value observed during the one-year study period was 38% or 20.5 ng/L. Median ratios with 95% limits of agreement were: 1.00(0.73-1.37); P=0.92 (1 week/baseline; n=77) and 1.07(0.52-2.25); P=0.19 (12 months/baseline; n=54). Baseline TnT was positively correlated with diabetes, ultrafiltration volume, arterial stiffness, change in intradialytic total peripheral resistance and N-terminal pro b-type natriuretic peptide (NT-proBNP) and negatively correlated with hematocrit, residual renal function and change in intradialytic cardiac output. High baseline TnT was associated with a higher risk of admission and cardiovascular (CV) events during follow-up. Increase in TnT over time (ΔTnT=12-months-baseline) was significantly associated with increase in left ventricular (LV) mass and NT-proBNP and decrease in LV ejection fraction and late intradialytic stroke volume. ΔTnT was not significantly associated with admissions, CV or intradialytic hypotensive events during follow-up.
Admissions were significantly more likely with a high (TnT-amplitude>20.5 ng/L) than a low TnT-amplitude. Peaks in TnT were less frequent in aspirin-treated patients.

Conclusion

ARB-treatment had no significant effect on TnT-levels. Week-to-week variation was generally low, yet over 12 months individual patients had considerable TnT fluctuations. Rise in TnT over time was significantly correlated with markers of cardiac deterioration.

Introduction

Hemodialysis (HD) patients have a high prevalence of cardiovascular (CV) disease and increased risk of myocardial infarction (MI) (1). Troponin T (TnT) is a small protein (37 kDa), which acts as the tropomyosin-binding and thin filament-anchoring subunit of the troponin complex, that regulates contraction in cardiac and skeletal muscles (2). The development of high-sensitive assays permits detection of very low levels of cardiac TnT and a clinically relevant increase in TnT is stated as one that exceeds the 99th -percentile of a normal reference population (3). HD patients, however, often have chronically elevated TnT as documented by multiple studies (4–8). The underlying pathophysiology may reflect coronary artery disease(9, 10), subclinical myocardial injury(10), myocardial stunning(11), left ventricular (LV) hypertrophy(12), reduced renal clearance(13) and circulatory congestion(10). The diagnosis of MI in these patients often relies on a higher cut-off value or assessment of the dynamic change in TnT, typically stated as a > 20% increase 6–9 hours after presentation or by comparison with previous values (14). In otherwise stable and asymptomatic HD patients, interpretation of elevated TnT remains a challenge for the clinician. Especially given the fact that even without suspected acute coronary syndrome higher TnT-levels are associated with a worse prognosis with a 2- to 4-fold increased 3-year mortality rate (15). Yet, although, higher levels in cross-sectional studies are associated with worse outcome, relatively little is known about short- and long-term changes in individual HD patients. Thus, from a clinical viewpoint it is important to know the expected range, variation over time, and the impact of clinical and dialysis specific factors. In addition, few interventional studies exist. Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) consistently induce strong regression of LV-hypertrophy and
fibrosis (16–18). Improvement of cardiac performance via LV-regression due to blockade of the renin-angiotensin-aldoosterone system (RAAS) should thus potentially lower TnT-levels. The aim of the present study was therefore to investigate the effect of the ARB irbesartan on TnT-levels, short and long-term variation in TnT and associations with various clinical and dialysis related parameters in a cohort of newly started HD patients participating in the SAFIR study (19-22).

Methods

Study design

The study protocol and results on intermediate CV endpoints and residual renal function have previously been published (19–22). Briefly, the SAFIR-study (acronym for “SAving residual renal Function in hemodialysis patients receiving IIRbesartan) was designed as a double blind multicenter randomized placebo-controlled trial primarily focusing on residual renal function and intermediate CV endpoints. The inclusion criteria were dialysis vintage < 1 year, left ventricular ejection fraction > 30% (echocardiography) and urinary output > 300 mL/day. Patients with myocardial infarction or unstable angina pectoris three months prior to admission were excluded. Patients were recruited from six Danish hospitals and followed for one year. Inclusion began in May 2009. The last patient’s last visit took place in December 2012.

Study medication and blood pressure

The study medication consisted of the ARB irbesartan 150 mg, or matching placebo. The initial dose was 150 mg/day. After two weeks, daily dose was increased to 300 mg/day. Irbesartan is not removed by dialysis and timing of drug administration was not specified due to the long lasting effect of irbesartan (plasma half-life is 15 hours) (23, 24). Compliance was checked monthly by counting residual tablets. Patients receiving RAAS-blocking agents such as ACEI or ARB at inclusion stopped this treatment one week before baseline. To reach equal blood pressure (BP) levels in the two treatment groups, investigators were instructed to achieve a predialytic systolic BP of 140 mmHg in all patients by adjusting dryweight and by use of all classes of antihypertensive drugs other than RAAS-blocking agents. Timing and intake of additional antihypertensive drugs was not specified. Details regarding blood pressure have previously been published (19–22).
Laboratory procedures

Venous blood samples were taken before HD in lithium-heparin-coated tubes after 30 minutes of rest in the supine position. Samples were centrifuged, and the separated plasma (5 mL) was stored at -80 °C. Plasma levels of TnT were measured with a previously validated automated Roche high sensitivity TnT immunoassay (Troponin T hs STAT Roche Diagnostics, Mannheim, Germany) on a Cobas e601 analyser according to the instructions of the manufacturer. The assay uses two cardiac TnT-specific mouse monoclonal antibodies in a sandwich format. The antibodies recognize epitopes located in the central part of the TnT molecule (amino acid positions 125–131 and 135–147, respectively). The assay does not exhibit significant cross-reaction with other troponins (skeletal muscle troponin T, cardiac/skeletal troponin I or human troponin C). Detection limit is 5 ng/L with a total imprecision of less than 10% at a level of 13 ng/L, and in 616 healthy volunteers, the upper 99th percentile was 13.5 ng/L (25). Analytical within assay coefficient of variation in HD patients is approximately 1.7-6% according to previous studies (26–28). N-terminal pro b-type natriuretic peptide (NT-proBNP) methodology has previously been described in detail (21).

Arterial stiffness

Pulse wave velocity (PWV) was obtained by sequential 10–20 seconds pulse wave recordings at the carotid artery and femoral artery using the intersecting tangent algorithm using the SphygmoCor system (version 7.0 and 8.2, Atcor Medical, Sydney, Australia) as previously described (19, 21).

Intradialytic parameters and measurements

All dialysis sessions in the study period were reviewed for episodes of intradialytic hypotension (IDH) defined as symptomatic hypotension requiring administration of intravenous fluid or preterm ending of the dialysis session as described previously (22). Cardiac output (CO) was measured in duplicate by injecting a bolus of 30 mL 37 °C isotonic saline into the venous blood line within the first and the last 30 minutes of the dialysis session using a previously validated method (Hemodialysis Monitor HD02/HD03, Flow-QC tubing sets, and clipon flow/dilution sensors Transonic Systems Inc., Ithaca, NY, USA) as previously described (22). The mean arterial blood pressure (MAP), total peripheral resistance (TPR), and stroke volume (SV) were derived by:
\[ MAP = \text{Diastolic BP} + \frac{1}{3} \cdot (\text{Systolic BP} - \text{Diastolic BP}) \]

\[ CO = SV \cdot \text{Heart rate} = \frac{MAP}{TPR} \]

Echocardiography

Echocardiography and quantification of cardiac chamber size, LV mass and function was performed as previously described (19, 21) in accordance with current guidelines (29).

Sample size and power calculations

Power calculations were based on the primary endpoints (LVH, PWV and residual renal function) and showed a need for 22–24 patients in each group to complete the study. However, in expectation of 40% dropout (e.g. transplantation, adverse events), we decided to recruit 80 patients (19).

Statistics

Data were analyzed with Stata/IC 12.1 (StataCorp LP, College Station, TX 77845 USA). The assumption of normality was checked with QQ-plots and analysis was performed using naturally log-transformed TnT due to skewness. Baseline data (qualitative variables) and various patient distributions were analyzed with \( \chi^2 \)-test and continuous variables were analyzed with t-test or Wilcoxon signed-rank test. Students t-test and a multivariate repeated measurements model (xtmixed) with time and drug (placebo or ARB) and the interaction between them as factors, which allows for missing values and dropout were used for comparison of placebo vs. ARB as previously described (21, 30). Variation over time was assessed with Bland-Altman plots and paired t-tests. Sets of duplicate log(TnT)-values (e.g. baseline vs. 1 week) were used to calculate average within- and between subject coefficients of variation (\( CV_1 \) and \( CV_G \)) using variance component estimates obtained by xtmixed and the following equations:
\[ CV_I = \left( \exp \left( \sqrt{SD_{Within}^2} \right) - 1 \right) \cdot 100\% \]

\[ CV_G = \left( \exp \left( \sqrt{SD_{Within}^2 + SD_{Between}^2} \right) - 1 \right) \cdot 100\% \]

Bootstrapping was used to obtain a 95% confidence interval (95% CI) for both CV\(_I\) and CV\(_G\). Univariate and multivariate linear and logistic regression were used for analysis of correlations and clinical outcome. Pearson’s \(r\) was used to describe linear relationships. Intention-to-treat analyses were performed and \(P < 0.05\) was considered statistically significant. Values are presented as means with 95% CI unless otherwise stated. Additional details are given in the Supplement.

**Results**

**Patient characteristics**

Eighty-two patients were included in the study with forty-one in each group. One patient in the placebo group did not consent to storage of plasma samples for TnT-analysis and was therefore excluded (Fig. 1). Overall, the groups were similar at baseline (Table 1). Twenty-six patients did not complete the study, eleven in the placebo and fifteen in the ARB group. Reasons for dropout were not significantly different (21).

**Impact of ARB-treatment**

Individual and mean changes over time in placebo and ARB-treated groups are shown in Fig. 2. Median values with ranges can be found in Table 2 in order to facilitate interpretation. There were no significant differences between the groups during the study period and ARB-treatment did not significantly affect mean TnT-levels over the 12-month study period (\(P \geq 0.19\) in all tests for parallel curves, equal levels, and constant levels) as shown in Fig. 2. Changes between baseline and 12 months are given as median ratios (12 months/baseline) with 95% confidence intervals (95% CI) due to back-transformation from natural log-transformed mean values in the placebo and ARB group. Overall, median ratios were not significantly different, neither when using all available data
(estimates from the multivariate repeated measurement model 1), nor when excluding patients with incomplete data (estimates based on Student’s t-test) as shown in Fig. 2. CV-events, admissions and IDH episodes were not significantly different after 12 months and total number of events in the two groups (placebo/ARB) were: 90/61 (Admissions); 18/14 (CV-events) and 50/63 (IDH-events). CV-events consisted of (placebo/ARB): MI: 0/2; angina: 8/5; percutaneous coronary intervention (PCI): 2/1; coronary artery bypass grafting (CABG): 0/1; arrythmia: 4/3 and valvular diseases: 4/2.

Variation in TnT over time

Since ARB-treatment had no significant impact on TnT-levels, all samples were pooled into one group regardless of treatment status for analysis of variation over time. Figure 3 shows Bland-Altman plots, median ratios and corresponding within-subject (CV_I) and between-subject (CV_G) coefficients of variation regardless of treatment status. Median ratios with 95% limits of agreement (reference range for difference) were: 1.00(0.73–1.37); P = 0.92 (Baseline vs. 1 week) and 1.07(0.52–2.25); P = 0.19 (Baseline vs. 12 months), respectively. Corresponding CV_I and CV_G (95% CI) were: CV_I: 11.8 (5.8–14.5)%; CV_G 111.6 (91.3-130.3)% (Baseline vs. 1 week) and CV_I: 31.1 (15.2–34.0)%; CV_G: 109.9 (90.1-129.7)% (Baseline vs. 12 months). Median change (min; max) after 12 months was: 3(-101; 368) ng/L (all samples; n = 54). Median (5th -95th -percentile range) week-to-week and one-year individual TnT-variation were: 0(-14-10)ng/L (baseline-1 week: n = 77) and 3(-40-71)ng/L (baseline-12 months: n = 54) as shown in Fig. 4A-B. Using a 20% change in TnT as cut-off (typically used for MI-diagnosis), 7.8% (6/77 patients) had > 20% increase in TnT and 2.6% (2/77 patients) had > 20% decrease in TnT one week after baseline. At 12 months 20.4% (11/54 patients) had > 20% increase in TnT and 22.2% (12/54 patients had > 20% decrease in TnT (Fig. 4C-D). Median (5-95th -percentile range) TnT amplitude in patients with 12-months of follow-up (n = 54) was 20.5(4-395)ng/L (Fig. 4E). Using data from all patients regardless of time in the study (n = 81), individual median amplitude (max-min) over the entire 12-month period was 14(0-1611) ng/L corresponding to range/median 30(0-4131)%). After removal of 3 outliers (TnT > 400 ng/L) individual median amplitude (min-max) over the entire 12-month period was 14(0-114)ng/L (Fig. 4F) corresponding to range/median 29(0-208)%.
samples from patients with complete 12-months follow-up (n = 54), individual median amplitude (max-min) over the entire 12-month period was 20.5(3-1611) ng/L corresponding to range/median 38(15-4131)%. After removal of 3 outliers (TnT > 400 ng/L) individual median amplitude (min-max) over the entire 12-month period was 18(3-114)ng/L corresponding to range/median 36(15-165)%. Most patients exhibited minor TnT-fluctuations close to the median. However, a low median TnT-level did not exclude subsequent rise in TnT (Fig. 4G-H).

Baseline TnT correlations (univariate analysis)
Baseline log-transformed TnT was positively correlated with age, diabetes, Charlson comorbidity index, Ultrafiltration (UF) volume, arterial stiffness (PWV and PWV-tertiles)), change in intradialytic total peripheral resistance (ΔTPR = TPR_{end} - TPR_{start}) and NT-proBNP. Baseline TnT was negatively correlated with change in intradialytic cardiac output (ΔCO = CO_{end} - CO_{start}), hematocrit and residual renal function (urine volume and GFR) as shown in Table 3. Echocardiographic parameters such as LV mass index and LV ejection fraction (LV EF) were not significantly associated with baseline TnT in univariate analysis. The impact of arterial stiffness on baseline TnT was examined further by splitting baseline PWV into tertiles as shown in Fig. 5. Known heart disease at baseline was only borderline significant (P = 0.06). Multivariate regression analysis was also performed with baseline log(TnT) as outcome and results are shown in the Supplement (Table S1).

Prediction of clinical events based on baseline TnT
High baseline TnT increased the risk of admission and CV-events (0 vs. ≥1 admissions/CV-events) during follow-up with natural log-transformed TnT odds-ratios (ORs): 2.62(1.22–5.64); P = 0.01 and 2.25(1.04–4.86); P = 0.04, respectively (Table 5). In multivariate analysis with additional adjustment for known heart disease, dialysis vintage, diabetes, age and LV EF both remained significant and adjusted ORs (0 vs. ≥ 1 event) were: 4.61(1.68–12.65); P = 0.003 and 3.71(1.23–11.17); P = 0.02, respectively. Baseline TnT was also borderline significant in terms of predicting IDH-events (0 vs. ≥1 events) during follow-up with natural log-transformed TnT OR: 1.87(0.98–3.59); P = 0.06.

Parameters associated with change in TnT
Increase in TnT over time ($\Delta = 12$-months-baseline) was significantly associated with increase in LV mass and NT-proBNP and decrease in LV EF and late intradialytic stroke volume 30 minutes before end of HD ($\Delta SV2$) in univariate analysis (Table 4). Results from multivariate analysis are shown in the Supplement (Table S2).

Changes in TnT over time and correlations with clinical outcome

Three different approaches were used to investigate the relationship between change in TnT over time and clinical outcome in terms of hospital admissions, CV-events and IDH episodes (Table 5). Regardless of whether change in TnT ($\Delta = 12$ months-baseline) was assessed as $\Delta \log$(TnT) or as a dichotomized outcome increase ($\Delta$TnT > 0) vs. decrease ($\Delta$TnT \leq 0) it was not significantly associated with admissions and CV-events during follow-up. In logistic regression analysis, TnT-increase after 12-months was associated with a lower risk of IDH-events with (TnT-increase vs. TnT-decrease) $OR: 0.31(0.10–0.96); P = 0.04$. However, in multivariate analysis with additional adjustment for LV mass, baseline UF volume and p-albumin it was no longer significant and adjusted $OR (\Delta$TnT > 0 vs. $\Delta$TnT \leq 0) was: $0.60(0.16–2.25); P = 0.45$.

TnT-amplitude

TnT-amplitude (max-min) was used to capture the change from the lowest to the highest TnT-value during the entire study period. If analysis was restricted to patients with complete 12-months follow-up ($n = 54$), the median TnT-amplitude was 38% or 20.5 ng/L as previously mentioned. By dichotomizing the amplitude into low (TnT \leq 20.5 ng/L) or high (TnT > 20.5 ng/L), high TnT-amplitude was significantly associated with increased number of admissions, borderline significant in terms of IDH episodes and non-significant in terms of CV-events. Using univariate logistic regression analysis, ORs (0 vs. $\geq$ 1 event) for comparison of high vs. low TnT-amplitude were: $4.60(1.24–16.97); P = 0.02$ (admissions) and $3.08(0.97; 9.67); P = 0.05$ (IDH-episodes). Adjusted ORs (0 vs. $\geq$ 1 event) from multivariate analysis were: $5.74(1.38–23.93); P = 0.02$ (admissions; adjusted for known heart disease, dialysis vintage, diabetes, age and LV EF) and $2.31(0.63–8.46); P = 0.21$ (IDH-episodes; adjusted for LV mass, baseline UF volume and p-albumin), respectively.

TnT-peak frequency
The number of TnT-peaks (defined as 20% increase above the individual patient TnT-median calculated from all available samples regardless of time in the study) were assessed. TnT-peak distribution in our cohort was (number of patients): No peak: 46(57%); 1 peak: 25(31%); 2 peaks: 9(11%); and 3 peaks: 1(1%). Baseline TnT-level, ARB-treatment, known heart disease, diabetes and arterial stiffness (baseline PWV-tertiles) had no significant impact on peak frequency. In univariate logistic regression analysis, the risk of admission tended to increase with the number of TnT-peaks with OR (0 vs. ≥ 1 admission) 2.30(1.00-5.30); P = 0.05. In multivariate analysis with adjustment for known heart disease, dialysis vintage, diabetes, age and LV EF this remained borderline significant with OR 2.30(0.99–5.40); P = 0.05. The frequency of CV-events or IDH-episodes was not significantly different when comparing patients without peaks to those with peaks.

Aspirin vs. non-aspirin treatment

In univariate logistic regression analysis, aspirin treatment decreased the risk of TnT-peaks (0 vs. ≥ 1 TnT peak) with OR: 0.28(0.11–0.72); P = 0.008. This remained significant in multivariate analysis (adjusted for known heart disease, diabetes, age, LV EF, and arterial stiffness) with OR: 0.24(0.07–0.80); P = 0.02. Admissions, CV and IDH events were not significantly different in aspirin vs. non aspirin treated. Additional details are given in the Supplement.

Discussion

This study found no significant impact of long-term treatment with the ARB irbesartan on predialytic TnT-levels in HD patients. Overall, TnT was quite stable with an individual median ratio over the entire 12-month period with 95% limits of agreement of 1.07(0.51-2.25). Yet, during 12 months of observation some patients exhibited a significant rise in TnT and a low median TnT-level did not exclude subsequent rise in TnT. Our study investigated various clinical and dialysis related parameters associated with TnT. Diabetes, UF, arterial stiffness (PWV), change in intradialytic total peripheral resistance and NT-proBNP were positively correlated with baseline TnT whereas hematocrit, residual renal function (GFR or urine volume) and change in intradialytic cardiac output were negatively correlated with baseline TnT.

The strengths of this study include serial measurements which allowed us to describe both short (one
week) and long-term (12 months) TnT-changes in our cohort. Within-subject and between-subject coefficients of variation were similar to previous studies in HD patients using high-sensitivity TnT-assays when comparing short-term estimates (27, 28). Unlike most previous studies our study included intervention with an ARB, and patients were well characterized regarding cardiac status (e.g. LV mass, LV EF and NT-proBNP), arterial stiffness, intradialytic hemodynamics, medications and clinical events. To the best of our knowledge, our study is the first to examine the impact of long-term ARB-treatment on TnT-levels in HD patients in a randomized double-blind placebo-controlled design.

LV hypertrophy (LVH) is frequent in end-stage renal disease (ESRD) (31–33) and with manifest LVH, myocardial capillary growth is expected to lack behind cardiomyocyte hypertrophy causing cardiomyocyte/capillary mismatch leading to increased oxygen diffusion distance, reduced ischemic tolerance of the heart, which in turns leads to subclinical ischemia of the myocardium and thereby amplified leakage of cardiac troponins including TnT (10). RAAS-blocking agents such as ACEI or ARB are generally considered to be beneficial in terms of regression of LVH (18) and improvement in LV EF (34). As previously reported (21), we found no significant effect of ARB-treatment on BP, LV mass and LV EF and our patients did not exhibit pronounced LVH or heart failure, which may explain why there was no significant impact of ARB-treatment on TnT in our study. Not many studies have examined long-term changes in TnT with serial measurements beyond six months like our study. Conway et al. examined 75 HD patients out of which 46 completed 4 serial pre- and post HD TnT measurements after 15 months (35). TnT was frequently elevated and baseline TnT-levels were associated with an increased risk of mortality and acute coronary syndrome. Bloch et al. followed 238 HD patients out of which 164 completed 24 months of follow-up using pre-HD TnT-measurements at baseline, 18 and 24 months, respectively (4). TnT increased by 50% in < 1/3 of patients and doubled in only 10% of patients during 18- and 22-months follow-up. Baseline TnT was a significant predictor of all cause and CV death. Mongeon et al. followed 100 HD patients out of which 78 completed 12 months of follow-up using both pre- and post-HD measurements at baseline, 6 months and 12 months, respectively (36). TnT was found to be stable over a 12-month period although levels tended to increase more between 6 and 12 months. Pre- and post-HD levels were similar, but higher TnT-levels were found in patients
with coronary artery disease. Finally, Roberts et al. studied the impact of carvedilol vs. placebo on TnT in a mixed cohort of 72 patients including both HD and peritoneal dialysis (PD) patients (37). TnT was measured at baseline, 6 months and 12 months, respectively. Forty-nine patients completed run-in and 31 completed 12-month follow-up. TnT-levels at baseline and during follow-up were similar to our study and there was no significant change in mean TnT-levels +/- Carvedilol treatment. Individual variation and correlation with clinical outcome were not reported. Our study thus adds significantly to our understanding of especially the temporal variation and on the impact of ARB-treatment on TNT in HD-patients.

High baseline TnT was in our study associated with a higher risk of admission and CV-events during follow-up. Elevated TnT is a well-known risk factor for negative outcome even when MI is not suspected in large cohorts of HD patients (15). Our findings are in line with this although strictly speaking our study was not powered for hard endpoints. Moreover, our study was able to demonstrate that rise in TnT over 12 months was significantly correlated with deterioration of cardiac status (increase in LV mass and NT-proBNP and decrease in LV ejection fraction and late intradialytic stroke volume). Despite this, rise in TnT after 12 months was not significantly associated with admissions, CV or IDH events during follow-up. We suspect this could be due to the relatively low number of patients in our study. We did demonstrate that a high TnT-amplitude (> 20.5 ng/L) was significantly associated with increased number of admissions and borderline significant in terms of IDH-episodes regardless of placebo/ARB-treatment status suggesting a link between IDH and myocardial damage in accordance with a previous study (38). Similarly, we found that admissions tended to be more likely in patients with ≥ 1 peak in TnT (defined as a 20% increase above the individual patient TnT-median) compared to non-peakers.

The relatively low TnT-levels in our study suggest occurrence of predominately minor myocyte injury. Previous studies investigating the impact of dialysis on TnT-levels showed that TnT may increase after HD due to hemoconcentration(35) but generally reported little change(5, 36) or even a slight reduction in TnT after HD (39). Nevertheless, the hemodynamic stress associated with dialysis including fluctuations in electrolytes and large UF volumes could be associated with a transient
increase in TnT and repeated HD sessions could lead to a progressive increase in TnT over time in some patients as previously reported (4, 35, 36).

The relationship between increased arterial stiffness, a hallmark of ESRD, and TnT-levels was a novel finding which may reflect compromised myocardial perfusion due to early return of the arterial pulse wave during systole rather than diastole (40). Increased arterial stiffness and low hematocrit combined with LVH and a high prevalence of coronary artery disease substantially augments the risk of ischemia and TnT-release. Impairment of myocardial function induced by dialysis treatment, known as cardiac stunning, may also contribute (11). Jefferies et al. demonstrated that the prevalence of myocardial stunning can be reduced with increasing intensity (frequency and duration) of HD and that there was a strong positive relationship between UF rate and severity of stunning as well as a tendency towards lower levels of TnT with frequent dialysis (41). Our study found that TnT-levels tended to increase with increased UF volume and a drop in intradialytic cardiac output. Since our study did not include home dialysis patients, we could not explore trends regarding HD frequency. Interestingly, we found that use of aspirin vs. non-use was associated with fewer TnT-peaks during follow-up. There is a paucity of definitive data concerning the efficacy of aspirin in dialysis patients and most observational studies suffer from confounding by indication explaining why some studies found aspirin use to be associated with increased CV mortality or adverse CV-events (42–44). Our study, although not designed to study the effects of aspirin, suggest that aspirin may be beneficial in terms of preventing asymptomatic ischemia in HD patients consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guideline (45).

Limitations
First of all, our findings are limited to HD patients free of heart failure, without recent episodes of angina or MI, with some preserved renal function and a relatively short time on dialysis. CV disease and instability during HD may be more prevalent among more morbid and fragile patients. We did not collect blood samples after dialysis and our results therefore reflect the predialytic state. In addition, samples were not collected based on suspicion of myocardial ischemia and may therefore underestimate the true variance. Due to preserved urine output in the majority of our patients,
relatively small UF volumes were prescribed during HD compared to other studies (46, 47). In HD patients with more pronounced CV disease or larger fluid fluctuations, the fluctuations in TnT may differ as well as the response to ARB-treatment. In our cohort, ARB-treatment did not significantly reduce BP and results could have been different in the presence of a BP difference. Patients treated with PD may respond differently in terms of TnT-fluctuations and response to ARB (48).

Conclusions
The ARB irbesartan had no significant impact on predialytic TnT-levels. Week-to-week TnT-variation was low, yet over 12 months individual patients had considerable TnT fluctuations. The median TnT-amplitude, capturing the change from the lowest to the highest TnT-value observed during the 12 months study period was 38% or 20.5 ng/L. High TnT at baseline was associated with a higher risk of admission and CV-events during follow-up. Admissions during follow-up were significantly more likely with a high (TnT-amplitude > 20.5 ng/L) than a low TnT-amplitude. Aspirin use was associated with fewer peaks in TnT and may prove beneficial in terms of preventing cardiac damage in HD patients. Regular monitoring of TnT may improve the ability to diagnose deterioration of cardiac status in otherwise asymptomatic HD patients but requires further studies prior to implementation into clinical praxis.

Abbreviations
ACEI
Angiotensin converting enzyme inhibitor
ARB
Angiotensin II receptor blocker
BP
Blood pressure
CABG
Coronary artery bypass grafting
CO
Cardiac output
ΔCO
Change in intradialytic cardiac output (ΔCO = CO_{end} - CO_{start})
CV
Cardiovascular

CV\textsubscript{G}

Between-subject coefficient of variation

CV\textsubscript{I}

Within-subject coefficient of variation

DDD

Defined daily doses

EF

Ejection fraction

EVF

Erythrocyte volume fraction

ESRD

End-stage renal disease

GFR

Glomerular filtration rate

HD

Hemodialysis

IDH

Intradialytic hypotensive episodes

LV

Left ventricular

LVH

LV hypertrophy

MAP

Mean arterial blood pressure

MI

Myocardial infarction

NT-proBNP

N-terminal pro b-type natriuretic peptide

OR

Odds ratio

PCI

Percutaneous coronary intervention

PD
Peritoneal dialysis
preHD
Pre-hemodialysis
PWV
Carotid-femoral pulse wave velocity
RAAS
Renin-angiotensin-aldosterone system
SAFIR
Acronym for SAving residual renal Function in hemodialysis patients receiving Irbesartan
SV
Stroke volume
SV1
Early intradialytic stroke volume within 30 minutes after start of HD
SV2
Late intradialytic stroke volume 30 minutes before end of HD
TnT
Troponin T
TPR
Total peripheral resistance
ΔTPR
Change in intradialytic total peripheral resistance (ΔTPR = TPR_{end} - TPR_{start})
UF
Ultrafiltration
Tables
Table 1

**Patient characteristics**
Demographics

|                      | Placebo (n=40) | ARB (n=41) |
|----------------------|---------------|------------|
| Age                  | 62±14         | 61±16      |
| Gender (males)       | n (%)         |            |
| Body weight          | 81±17         | 79±17      |
| Body mass index      | 27±5          | 26±5       |
| Diabetes             | n (%)         |            |
| Heart disease        | n (%)         |            |
| Ischemic heart disease| n (%)        |            |
| Charlson co-morbidity index | 3.5±1.6     | 3.8±1.9    |
| LV mass index        | 126±36        | 126±33     |

Cardiac medications

|                      | Placebo (n=40) | ARB (n=41) |
|----------------------|---------------|------------|
| Aspirin treatment    | n (%)         |            |
| Antiplatelet (non-aspirin) drugs | n (%)   |            |
| Statin treatment     | n (%)         |            |
| Nitrate medication   | n (%)         |            |

BP and BP-medication

|                      | Placebo (n=40) | ARB (n=41) |
|----------------------|---------------|------------|
| Baseline systolic BP (preHD) | mmHg         |            |
| Baseline diastolic BP (preHD) | mmHg         |            |
| 12 month systolic BP (preHD) | mmHg         |            |
| 12 month diastolic BP (preHD) | mmHg         |            |
| BP-drugs excl. Placebo/ARB | n            |            |
| BP-drugs excl. Placebo/ARB | DDD          |            |

Dialysis parameters

|                      | Placebo (n=40) | ARB (n=41) |
|----------------------|---------------|------------|
| Time on dialysis     | days          |            |
| AV-fistula/central catheter | n (%) |            |
| Urine output         | L/24 hours    |            |
| Glomerular filtration rate | mL/min/1.73 m² |      |
| Frequency            | times/week    |            |
| HD-time              | hours/week    |            |
| Ultrafiltration      | L             |            |
| Urea reduction ratio | %             |            |
| Hematocrit (EVF)     |               |            |

Heart disease included various conditions such as ischemic heart disease, mild heart failure (LV EF>30%) and valvulopathy. Ischemic heart disease was defined by the presence of known ischemic heart disease, angina, pre-trial myocardial infarction, and pre-trial PCI or CABG treatment. LV: Left ventricular; EF: Ejection fraction; BP: Blood pressure; preHD: Pre-hemodialysis; DDD: Defined daily doses; EVF: Erythrocyte volume fraction

Table 2

TnT median values with ranges

| Time          | Group    | n     | TnT   | Group    | n     | TnT   |
|---------------|----------|-------|-------|----------|-------|-------|
| Baseline      | Placebo  | 40    | 45 (14-295) | All     | 81    | 45 (10-343) |
| ARB           | 41       | 46 (10-343) |
| 1 week        | Placebo  | 38    | 48 (17-303) | All     | 77    | 47 (10-305) |
| ARB           | 39       | 47 (10-305) |
| 3 months      | Placebo  | 35    | 59 (18-927) | All     | 70    | 51 (9-927) |
| ARB           | 35       | 48 (10-271) |
| 6 months      | Placebo  | 32    | 50 (17-267) | All     | 62    | 52 (10-1642) |
| ARB           | 30       | 56 (10-1642) |
| 9 months      | Placebo  | 32    | 46 (16-249) | All     | 61    | 48 (10-249) |
| ARB           | 29       | 52 (10-214) |
| 12 months     | Placebo  | 29    | 50 (16-210) | All     | 54    | 49 (13-451) |
| ARB           | 25       | 49 (13-451) |
TnT: Troponin T. Values are presented as median with range (min-max). Statistical analysis was performed after logarithmic transformation due to skewed data.

### Table 3

**Univariate regression analysis based on baseline log(TnT)**

| Parameter                              | n  | β (95% CI)                  | P       | r²    |
|----------------------------------------|----|-----------------------------|---------|-------|
| Age (years)                            | 81 | 0.01(0.00; 0.02)            | <0.05   | 0.05  |
| Female gender                          | 81 | -0.25(-0.60; 0.10)          | 0.15    | 0.03  |
| Cornell (Sv3+RavL) (mm)                | 81 | 0.02(0.00; 0.03)            | 0.08    | 0.04  |
| Diabetes                               | 81 | 0.45(0.11; 0.80)            | 0.01    | 0.08  |
| Heart disease                          | 81 | 0.32(-0.01; 0.65)           | 0.06    | 0.04  |
| Charlson comorbidity index             | 81 | 0.13(0.05; 0.22)            | 0.004   | 0.10  |
| GFR (mL/min/1.73m²)                    | 77 | -0.07(-0.13; -0.01)         | 0.02    | 0.07  |
| Urine output (L/24h)                   | 79 | -0.35(-0.57; -0.14)         | 0.001   | 0.12  |
| Ultrafiltration (L)                    | 81 | 0.23(0.11; 0.35)            | <0.001  | 0.16  |
| PWV (m/s)                              | 79 | 0.05 (0.00; 0.10)           | 0.04    | 0.05  |
| PWV-tertiles (m/s)                     |    |                             |         |       |
| 9.5-12.5                               | 26 | 0.36(-0.04; 0.76)           | 0.08    | 0.09  |
| >12.5                                  | 26 | 0.52(0.13; 0.92)            | 0.01    |       |
| LV mass index (g/m²)                   | 80 | 0.00(0.00; 0.01)            | 0.08    | 0.04  |
| LV EF (%)                              | 80 | -0.01(-0.03; 0.01)          | 0.20    | 0.02  |
| ΔCO (L/min)                            | 62 | -0.23(-0.39; -0.07)         | 0.007   | 0.12  |
| ΔTPR (mmHg/(L/min))                    | 61 | 0.07(0.01; 0.12)            | 0.03    | 0.08  |
| log(NT-proBNP) (log(nmol/L))           | 81 | 0.27(0.14; 0.39)            | <0.001  | 0.19  |
| Haematocrit (EVF)                      | 81 | -5.10(-8.68; -1.52)         | 0.006   | 0.09  |

TnT: Troponin T; GFR: Glomerular filtration rate; PWV: Carotid-femoral pulse wave velocity; LV: Left ventricular; EF: Ejection fraction; ΔCO: Change in intradialytic cardiac output (ΔCO = CO_{end} - CO_{start}); ΔTPR: Change in intradialytic total peripheral resistance (ΔTPR = TPR_{end} - TPR_{start}); NT-proBNP: N-terminal pro b-type natriuretic peptide; EVF: Erythrocyte volume fraction

### Table 4

**Univariate regression analysis with change in log(TnT) (∆=12 months-baseline)**
| Parameter | n | β (95% CI) | P | P² |
|-----------|---|------------|---|---|
| Age at baseline | 54 | 0.005(-0.002; 0.013) | 0.13 | 0.04 |
| Heart disease | 54 | 0.22(0.02; 0.42) | **0.03** | 0.08 |
| Diabetes | 54 | -0.12(-0.34; 0.09) | 0.25 | 0.03 |
| Charlson comorbidity index | 54 | -0.01(-0.07; 0.06) | 0.87 | 0.00 |
| ΔGFR (mL/min/1.73m²) | 49 | -0.03(-0.10; 0.04) | 0.40 | 0.01 |
| ΔUrine output (L/24h) | 52 | 0.04(-0.13; 0.21) | 0.63 | 0.00 |
| ΔUltrafiltration (L) | 53 | -0.02(-0.12; 0.08) | 0.68 | 0.00 |
| Baseline Cornell (SV3+RaVL) (mm) | 54 | 0.012(0.001; 0.022) | 0.03 | 0.09 |
| ΔCornell (SV3+RaVL) (mm) | 54 | -0.01(-0.02; 0.01) | 0.38 | 0.02 |
| Baseline PWV (m/s) | 53 | 0.01(-0.02; 0.04) | 0.55 | 0.01 |
| Baseline PWV-tertiles (m/s) | 9.5-12.5 | 27 | 0.09(-0.19; 0.37) | 0.52 | 0.02 |
| >12.5 | 26 | 0.13(-0.13; 0.38) | 0.32 | 0.00 |
| ΔPWV (m/s) | 52 | 0.01(-0.05; 0.06) | 0.74 | 0.00 |
| ΔLV mass index (g/m²) | 53 | 0.003(0.001; 0.006) | **0.01** | 0.11 |
| ΔLV EF (%) | 53 | -0.01(-0.02; 0.00) | 0.01 | 0.12 |
| ΔSV2 (mL) | 41 | -0.01(-0.01; 0.00) | 0.04 | 0.11 |
| Δlog(NT-proBNP) (log(nmol/L)) | 54 | 0.18(0.09; 0.27) | <0.001 | 0.25 |
| ΔHematocrit (EVF) | 54 | -0.93(-2.94; 1.09) | 0.36 | 0.02 |

Abbreviations:

TnT: Troponin T; GFR: Glomerular filtration rate; PWV: Carotid-femoral pulse wave velocity; LV: Left ventricular; EF: Ejection fraction; SV2: Late intradialytic stroke volume 30 minutes before end of HD; NT-proBNP: N-terminal pro b-type natriuretic peptide; EVF: Erythrocyte volume fraction

### Table 5

#### Univariate and multivariate logistic regression results

| | CV-events (0 vs. ≥1) | Admissions (0 vs. ≥1) | IDH-episodes (0 vs. ≥1) | TnT-peaks (0 vs. ≥1) |
|---|---|---|---|---|
| n | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate |
| Baseline TnT log(TnT) | 81 | **2.25**(1.04-4.86) | **3.71**(1.23-11.17) | **2.62**(1.22-5.64) | **4.61**(1.68-12.65) | 1.87(0.98-3.59) | 1.41(0.64-3.13) | 0.94(0.52-1.71) | 1.06(0.52-2.14) |
| Low (TnT≤45 ng/L) vs. High (TnT>45 ng/L) | 81 | 1.72(0.58-5.09) | 2.23(0.64-7.75) | **3.74**(1.29-10.86) | **5.67**(1.66-19.40) | **2.68**(1.05-6.79) | **2.37**(0.77-7.33) | **0.84**(0.35-2.03) | **0.76**(0.27-2.09) |
| TnT change (Δ=12 months-baseline) | 54 | 1.17(0.20-6.93) | 0.43(0.03-6.90) | 0.64(0.14-2.91) | 0.38(0.07-2.17) | 0.26(0.04-1.56) | 0.68(0.09-5.12) | - | - |
| Δlog(TnT) | 54 | 0.76(0.19-3.01) | 0.20(0.03-1.54) | 0.30(0.08-1.10) | **0.17**(0.04-0.78) | 0.31(0.10-0.96) | 0.60(0.16-2.25) | - | - |
| Increase (ΔTnT>0) vs. Decrease (ΔTnT≤0) | 54 | 0.61(0.15-2.46) | 0.79(0.14-4.44) | **4.60**(1.24-16.97) | **5.74**(1.38-23.93) | 3.08(0.97-9.67) | 2.31(0.63-8.46) | - | - |
| TnT amplitude (max-min) | 54 | 0.90(0.40-2.02) | 2.30(1.00-5.30) | 2.30(0.99-5.40) | 1.33(0.73-2.44) | 1.22(0.63-2.35) | - | - |
| Low (TnT≤20.5 ng/L) vs. High (TnT>20.5 ng/L) | 81 | 1.05(0.51-2.15) | 0.90(0.40-2.02) | 2.30(1.00-5.30) | 2.30(0.99-5.40) | 1.33(0.73-2.44) | 1.22(0.63-2.35) | - | - |
| TnT-Peaks No peak vs. ≥1 peak | 81 | 1.96(0.66-5.80) | 2.00(0.52-7.70) | 0.54(0.20-1.44) | 0.55(0.17-1.73) | 0.69(0.28-1.73) | 0.82(0.28-2.39) | **0.28**(0.11-0.72) | **0.24**(0.07-0.80) |

Aspirin (n=37) vs. non-aspirin treatment (n=44)
Multivariate models:

*) Known heart disease, dialysis vintage, diabetes, age, LV ejection fraction

§) LV mass index, baseline ultrafiltration volume and plasma albumin dichotomized into low<3.9 g/dL or high (3.9 g/dL=median value) and if n=81 also time in the study

#) Known heart disease, diabetes, age, LV ejection fraction, and arterial stiffness (PWV-tertiles)

Abbreviations:

TnT: Troponin T; TnT-peak: 20% increase above individual TnT median value; CV: Cardiovascular;
IDH: Intradialytic hypotensive episodes defined as symptomatic hypotension requiring administration of intravenous fluid or preterm ending of the dialysis session.

Declarations

Ethics declarations

Ethics approval and consent to participate

The study was conducted in accordance with good clinical practice (GCP) and the ethical standards described in the Helsinki Declaration. All participating sites were monitored by a local independent GCP-Unit. Written informed consent was obtained from all participants. The Central Denmark Region Committees on Biomedical Research Ethics, the Danish Health and Medicines Authority, and the Danish Data Protection Agency approved the study.

ClinicalTrials.gov Identifier: NCT00791830

EudraCT no: 2008-001267-11

Consent for publication

Consent for publication is not applicable to this manuscript.

Availability of data and materials

The datasets that support the findings of the current study are available from the corresponding author on reasonable request.

Competing interests

Dr. Bibby reports personal fees from Kidney International and Kidney International Reports although
not related to this paper. Besides funding sources, the other authors have declared that no competing interests exist.

**Funding**

The SAFIR study was primarily supported by The Danish Council for Independent Research Medical Sciences, but also by (in alphabetical order): Aase og Ejnar Danielsens Fond, Beckett-Fonden, Civilingeniør Frode Nygaard og Hustrus Fond, The Danish Society of Hypertension, The Danish Society of Nephrology, Direktør Kurt Bønnelycke & Hustru Grethe Bønnelyckes Fond, Fabrikant Karl G Andersens Fond, Fausbølls Helsefond, Fonden til udvikling og uddannelse ved Nyremedicinsk Afdeling ved Aarhus Universitetshospital, Fresenius Medical Care Denmark, Frimodt-Heineke Fonden, Helen & Ejnar Bjørnows Fond, The Institute of Clinical Medicine at Aarhus University, Kirsten Anthonius’ Fond, Leo Pharmas Hypertensionslegat, Nyreforeningens Forskningsfond, Overlæge Poul M Christiansen & Hustrus Fond, Region Midtjylland's Sundhedsvidsenskabelige Forskningsfond, Snedkermester Sophus Jacobsen and Hustru Astrid Jacobsens Fond. Sanofi Denmark provided original study medication (placebo and active tablets) free of charge and financially supported some meeting activity. NorDiaTech Denmark provided one Transonic Flow-QC Hemodialysis Monitor for three years including yearly calibration. The funders including Sanofi Denmark and NorDiaTech Denmark had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Authors’ contributions**

KK, CDP, BJ and JDJ conceptualized the study. CDP is the principle author and drafted the manuscript. KLC is a senior cardiology consultant who provided valuable input given his extensive experience with blood pressure research and greatly aided in the interpretation of the data. JDJ is a senior hemodialysis consultant who contributed to data analysis, preparation of figures and drafting of the manuscript. BJ is a senior consultant and professor in nephrology responsible for the SAFIR-study and oversaw the work. CDP and KK were both principal investigators in the SAFIR-study and contributed to data collection, database preparation, literature review and writing. BMB provided statistical support and contributed to writing the statistical part of the Methods section and Results section. All authors contributed to, reviewed and approved the manuscript including all its drafts. All authors read and
approved the final manuscript.

Acknowledgements

We acknowledge the great efforts and contributions of the study nurses and study participants from the six hospitals participating in the SAFIR study. Lab technicians Ilse Rasmussen and Lotte Kristine Cornelius Lassen are thanked for their assistance with blood samples and assays.

A subset of data was presented as posters at American Society of Nephrology Kidney Week 2016 in Chicago, IL, USA (Abstract FR-PO925 available from: https://www.asn-online.org/abstracts/) and at Artery 2018 meeting in Guimarães, Portugal (https://doi.org/10.1016/j.artres.2018.10.203).

References

1. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65(6):2380-9.

2. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115(13):e356-75.

3. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634-53.

4. Honneger Bloch S, Honneger S, Semple D, Sidhu K, Stewart R, Pilmore H. Prognostic value and long-term variation of high sensitivity troponin T in clinically stable haemodialysis patients. N Z Med J. 2014;127(1402):97-109.

5. Pianta TJ, Horvath AR, Ellis VM, Leonetti R, Moffat C, Josland EA, et al. Cardiac high-sensitivity troponin T measurement: a layer of complexity in managing haemodialysis patients. Nephrology (Carlton). 2012;17(7):636-41.

6. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic
haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant. 2001;16(7):1452-8.

7. Wolley M, Stewart R, Curry E, Davidson J, White H, Pilmore H. Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. Clinical Kidney Journal. 2013;6(4):402-9.

8. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941-5.

9. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290(3):353-9.

10. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19(9):1643-52.

11. Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies HJ, McIntyre CW. Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol. 2012;7(8):1285-92.

12. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002;40(1):68-75.

13. Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109(1):23-5.

14. Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac
troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53(12):2086-96.

15. Michos ED, Wilson LM, Yeh HC, Berger Z, Suarez-Cuervo C, Stacy SR, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161(7):491-501.

16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.

17. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19(6):1167-76.

18. Yang LY, Ge X, Wang YL, Ma KL, Liu H, Zhang XL, et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis. Am J Med Sci. 2013;345(1):1-9.

19. Peters CD, Kjærgaard KD, Jespersen B, Christensen KL, Jensen JD. Renal and cardiovascular effects of irbesartan in dialysis patients - a randomized controlled trial protocol (SAFIR study). Dan Med J. 2013;60(4):A4602.

20. Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2014;64(6):892-901.

21. Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, et al. No significant effect of angiotensin II receptor blockade on intermediate
cardiovascular end points in hemodialysis patients. Kidney Int. 2014;86(3):625-37.

22. Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, et al. Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study). PLoS One. 2015;10(6):e0126882.

23. Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TW, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. ClinPharmacolTher. 1997;62(6):610-8.

24. Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol. 1998;38(3):246-55.

25. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254-61.

26. Aakre KM, Roraas T, Petersen PH, Svarstad E, Sellevoll H, Skadberg O, et al. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clin Chem. 2014;60(6):838-47.

27. Corte Z, Garcia C, Venta R. Biological variation of cardiac troponin T in patients with end-stage renal disease and in healthy individuals. Ann Clin Biochem. 2015;52(Pt 1):53-60.

28. Mbagaya W, Luvai A, Lopez B. Biological variation of cardiac troponin in stable haemodialysis patients. Ann Clin Biochem. 2015;52(Pt 5):562-8.

29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber
Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.

30. Peters CD, Kjaergaard KD, Nielsen CH, Christensen KL, Bibby BM, Jensen JD, et al. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study). Hemodial Int. 2017;21(1):47-62.

31. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186-92.

32. Takeda A, Toda T, Iwamoto H, Watanabe K, Matsui N. Long-term evolution and changing associations of left ventricular hypertrophy after starting hemodialysis. Nephron ClinPract. 2008;110(2):c126-c32.

33. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36(2):286-90.

34. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, et al. Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure A Double-Blind, Placebo-Controlled Trial. Journal of the American College of Cardiology. 2010;56(21):1701-8.

35. Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant. 2005;20(12):2759-64.

36. Mongeon FP, Dorais M, Lorier JL, Froment D, Letendre E, Rinfret S. Effect of hemodialysis, coronary artery disease and diabetes on cardiac troponin T: a
prospective survey over one year. Open Cardiovasc Med J. 2009;3:69-77.

37. Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, et al. Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney Blood Press Res. 2017;42(6):1033-44.

38. Hung SY, Hung YM, Fang HC, Yeh JH, Hung GC, Wu CJ, et al. Cardiac troponin I and creatine kinase isoenzyme MB in patients with intradialytic hypotension. Blood Purif. 2004;22(4):338-43.

39. Badiou S, Boudet A, Leray-Moragues H, Rodriguez A, Bargnoux AS, Dupuy AM, et al. Monthly reference change value of cardiac troponin in hemodialysis patients as a useful tool for long-term cardiovascular management. Clin Biochem. 2016;49(15):1195-8.

40. Nichols WW, Michael F O'Rourke and Charalambos Vlachopoulos. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles 6th Edition: London, Hodder Arnold; 2011.

41. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011;6(6):1326-32.

42. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(4):872-81.

43. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50(4):602-11.

44. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev.
2013(2):CD008834.

45. KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
   http://www.kidney.org/professionals/KDOQI/guidelines_commentaries.cfm

46. Tislér A, Akócsi K, Hárshegyi I, Varga G, Ferenczi S, Grosz M, et al. Comparison of
dialysis and clinical characteristics of patients with frequent and occasional
hemodialysis-associated hypotension. Kidney Blood Press Res. 2002;25(2):97-102.

47. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an
independent risk factor for two-year mortality in hemodialysis patients. Kidney Int.
2004;66(3):1212-20.

48. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II
receptor blocker, valsartan, on residual renal function in patients on CAPD.
   AmJKidney Dis. 2004;43(6):1056-64.

Figures
Consort Flow Chart. Inclusion and exclusion criteria have been published previously (19).

Briefly, the main inclusion criteria were urine output >300 ml/day, dialysis vintage <1 year and left ventricular ejection fraction >30%.
Individual and mean log-transformed TnT at various time points. Mean changes (baseline-12 months) and mean differences between groups are given as median ratios with 95% CI due to back-transformation using estimates from both xtmixed (all available patient data regardless of time in the study) and Student’s t-test thereby excluding patients with incomplete data (only patients with complete 12-months follow up). Corresponding median TnT-values and ranges (min-max) are shown in Table 2.
Bland-Altman plots (A-E) showing variation in TnT over time (baseline vs. subsequent measurements). Median ratios due to back-transformation with 95% limits of agreement (reference range for difference) and corresponding within-subject (CVI) & between-subject (CVG) coefficients of variation with 95% confidence intervals (95% CI) are also given. Note logarithmic scale on Y-axis in all Bland-Altman plots.
Figure 4

A) Shows short-term TnT variation baseline vs. 1 week with patients sorted according to
magnitude of change in TnT (lowest to highest). B) Long-term TnT variation baseline vs. 12 months with individual patients sorted according to magnitude of change (lowest to highest).

C) Similar to A but with patients sorted according to magnitude of TnT ratio (1 week/baseline) D) Similar to B but with patients sorted according to magnitude of TnT ratio (12 months/baseline) E) TnT amplitude (max-min) from patients with complete 12 months follow-up with patients sorted according to magnitude of change (lowest to highest). F) TnT amplitude (max-min) from all patients, except outliers, regardless of time in the study with patients sorted according to magnitude of change (lowest to highest). G) Range (min & max) and median TnT from all patients sorted according to intervention (Placebo/ARB) regardless of time in the study. H) Range (min & max) and median TnT from all patients, except outliers, sorted according to median TnT regardless of time in the study.
Baseline pulse wave velocity (PWV) tertiles and log-transformed baseline TnT. The geometric baseline TnT-means with 95% confidence intervals (95%-CI) were: cfPWV<9.5 m/s (n=27): 35(26-56)ng/L; cfPWV 9.5-12.5 m/s (n=26): 50(38-66)ng/L; cfPWV>12.5 m/s (n=26): 59(44-78)ng/L.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplement TnT SAFIR BMJ_PLAIN_TEXT_050120.docx